lar lesion appears to be the only cause of the purpura. Histologically, the skin shows a perivascular inflammatory reaction which closely resembles that seen in thrombocytopenic cases. It is possible that the increased capillary fragility and the perivascular inflammatory reaction are due to the action of an antibody which acts only on endothelial cells rendered antigenic by union with the drug. No such antibody has, however, been demonstrated. Drug Agranulocytosis and Marrow Aplasia by M C G Israels MD FRCP (Manchester) Agranulocytosis Agranulocytosis occurs clinically in two forms, acute and chronic. It is the acute form that is most often associated with sensitivity to drugs. Chronic neutropenia is far from common and in most patients no definite cause can be found, but at the Royal Infirmary, Manchester, we have seen a few patients who had been taking drugs for long periods at some time and the presumably toxic effect had persisted.
Acute agranulocytosis was originally traced to amidopyrine. Several workers, Dr Wilkinson and myself included (Israels & Wilkinson 1937), were able to show that in a sensitive subject a minute dose of amidopyrine was sufficient to cause disappearance of the neutrophils from the blood also in a few hours. The neutrophils usually come back into the blood again within a few hours.
Amidopyrine is hardly ever used to-day, but a few proprietary mixtures still contain it: these drugs can easily be avoided. Since the time of amidopyrine many other drugs have been implicated; one textbook gives a list of 50. Fortunately many are doubtful reports about isolated cases, and the number of drugs that are really troublesome is in fact small.
After amidopyrine, the early sulphonamides, especially sulphapyridine, were responsible for a few cases. The next group to be troublesome was the thiouracils used as antithyroid drugs. Only some of the reported cases were fatal; many of the patients recovered when the drug was stopped. It was while studying thiouracil agranulocytosis that we found that examination of the bone marrow gave a good guide to prognosis. If there were still healthy myelocytes present, the patient usually recovered; on the other hand if the marrow was hypoplastic, most of the cells being lymphocytes, plasma and reticulum cells, the prognosis was very bad. Thiouracil agranulocytosis is rarely seen to-day; we use methyl thiouracit in much smaller doses than when it was first introduced. Carbimazole is usually considered to be the safest of the antithyroid drugs, but in the last six years, three reports of fatal agranulocytosis have appeared in British journals; all were acute cases and all the patients were having the recommended dose of 30 mg daily (Shaw 1955 , Burrell 1956 , Tait 1957 .
The latest drugs to cause agranulocytosis are the tranquillizers. Chlorpromazine, promazine, imipramine, meprobamate and pecazine have all been the subject of reports of agranulocytosis, not always fatal. Schick & Virks (1956) reviewed 21 cases due to chlorpromazine reported in the literature up to 1956: 13 had recovered. Many of the cases due to tranquillizers have been in patients who were in mental hospitals for the treatment of severe depression and were receiving considerable doses of the drugs. Gore & Biezanek (1956) gave pecazine to a depressed woman of 35; she had 75 mg daily for fourteen days, then 150 mg daily for four weeks. The drug was then stopped because a routine blood count showed 3,000 white cells per c.mm with 53 % polymorphs. Ten days later the W.B.C. numbered 850 with no polymorphs; the patient had sore throat, feverand headache and pharyngeal ulcers appeared. She recovered quite quickly. Cook et al. (1957) used promazine in a similar patient. She received 300 mg daily for two days and then 600 mg daily. On the twenty-fifth day she complained of sorethroat; on the twenty-seventh she had pyrexia and cervical adenitis; the W.B.C. was 1,900 and no polymorphs could be found. The sternal marrow showed only fatty tissue with no cellular areas. However, treated with penicillin, corticotrophin. Symposium on Drug Sensitization and blood transfusions, she also recovered. A similar promazine case reported by Earle (1957) , where the patient had received 150 mg a day for forty-four days, was fatal, and a fatal case following the use of imipramine andmeprobamate was reported by Curran & Barabas (1961) . Cohen (1960) reported a case due to imipramine; this drug had been given twice to the patient; in the second course she had received 225 mg daily for sixteen days when symptoms suggestive of agranulocytosis appeared and her W.B.C. numbered 1,100 with 4% neutrophils; she recovered quickly when the imipramine was stopped.
These reports are striking, but in view of the indiscriminate way these drugs are used, especially in other countries, and their potentiality for causing disturbances of blood formation, it is surprising that relatively so few cases have been reported.
Some other drugs have also been reported in the British literature over the past five years as potentially causing agranulocytosis. Amodiaquine is used in the treatment of malaria and for some chronic skin diseases associated with photosensitivity. A woman of 53 had been treated for such a skin condition with 200 mg amodiaquine daily for eight weeks; she developed typical and fatal agranulocytic angina (Glick 1957) . Chlorothiazide appeared to be the cause of a fatal case reported by Zuckerman & Chazan (1958) ; a total of 25 g had been given in thirteen days together with digoxin for the treatment of cardiac failure. Phenytoin sodium used for the treatment of epilepsy was reported to have caused agranulocytosis in a patient who had reasonable doses (Turner 1960) : this patient recovered when the drug was stopped. Finally-paracetamol seems to have been the cause of a non-fatal agranulocytopenia in a woman who had taken 2 to 4 tablets daily for many weeks (Lloyd 1961) : she also recovered.
But in spite of these reports and the many available potentially dangerous drugs, agranulocytic angina is very uncommon; no case has been admitted to the Manchester Royal Infirmary in the past five years. In this period we have seen 4 patients with chronic neutropenia; one of these might have been started by excessive drug taking. The patient was a psychologically unstable young woman who took phenacetin-aspirin-caffeine tablets in large numbers and who had made a suicidal attempt. She was referred to us because of recurrent infections. Her marrow showed very typically the almost complete absence of neutrophil granulocytes, but eosinophils and basophils were normal and erythroblasts were active. This is a very different picture from the hypoplastic marrow of acute agranulocytosis.
In agranulocytic angina, idiosyncrasy as much as accumulated toxicity seems to be the danger. Many reported cases have had quite reasonable therapeutic doses for short periods. This means that even regular checks of the white cell count are unlikely to give warning of an attack. Nevertheless, in patients receiving prolonged treatment with drugs that offer a possible risk, such as antithyroid drugs or tranquillizers, it is best to check the neutrophil count regularly so that the drugs can be stopped promptly if any unusual fall in the count occurs. The case records quoted show that this may not be too late.
Treatment with large doses of penicillin and blood transfusion is mostly given for acute agranulocytosis. Steroids are not recommended and pentose nucleotides are no longer used. For chronic neutropenia there is no treatment that will restore neutrophil formation; energetic treatment of any infection is a necessary measure. Splenectomy has been said to be useful, but these patients have rarely been followed for longer than six months post-operatively. The operation is not recommended.
Marrow Aplasia
There are some drugs in use that will always produce aplasia of the marrow if given in large enough doses or for long enough. Such drugs are the nitrogen mustards, antimetabolites like aminopterin and mercaptopurine, and other drugs used to suppress abnormal hiemopoiesis like busulphan and urethane. Ionizing radiation, whether in the form of X-rays or a therapeutic isotope, comes into the same group. It is drugs outside this group that sometimes cause aplasia that are to be discussed here. As with agranulocytosis, a long list of drugs have been reported to cause aplastic anmmia, but the number of frequently implicated drugs is in fact small. The organic arsenicals are much less used nowadays than formerly and theirlimits of tolerance are well established. Other drugs have taken their place. In the five years from August 1956 to August 1961 32 new patients with aplastic anamia were seen in my Department; 24 were idiopathic, in 4 the use of chloramphenicol seemed to be the cause, in one patient gold treatment had been given for rheumatoid arthritis, one patient had had methoin for epilepsy, and had been exposed to toxic solvents used in aircraft construction, and one case followed X-ray therapy for cancer. This sort of distribution is found in most recent reported series of cases of aplastic anemia.
Perhaps the most surprising finding is the liability of the antibiotic chloramphenicol to cause aplastic anamia. Scott et al. (1959) reported 30 cases of aplastic anemia of which 22 were due to drugs, and in 7 of these 22 chloramphenicol was the drug implicated. This particular risk associated with the use of chloramphenicol is now well known and most physicians restrict its use to infections in which the organism is sensitive to chloramphenicol and not to other antibiotics, and even then are careful to use it in short courses only. With these precautions chloramphenicol should cause aplastic ansemia as infrequently as other drugs.
In the past five years reports in the British literature of aplastic anmmia due to drugs other than chloramphenicol have been few. Venning (1957) reported a fatal case due to phenylbutazone; the patient had taken not less than 300 mg a day for twenty months for the treatment of rheumatoid arthritis; the cause of death was hemorrhage into the alimentary tract. Recently potassium perchlorate, used as an antithyroid drug, has twice been reported to have caused fatal aplastic anamia. Hobson (1961) described the case of a woman of 38 with recurrent hyperthyroidism; she had received 800 mg of potassium perchlorate daily for fourteen weeks and 600 mg daily for a further eighteen and a half weeks. The sternal marrow was completely aplastic and the patient died from a pulmonary infection. In the case recorded by Johnson & Moore (1961) , a woman of 29 with characteristic thyrotoxicosis was given I g daily of potassium perchlorate for three months with good clinical improvement; she then took 600 mg daily for a further month when the rapid onset of signs and symptoms of anamia occurred. Her hmemoglobin was down to 37 % and the marrow was found to be almost completely aplastic. She was kept alive with blood trans-fusions for six weeks but succumbed to a generalized septicimia.
The treatment of aplastic anemia is repeated blood transfusion supported by the administration of prednisolone 10-15 mg daily which helps to control hemorrhage. Heemorrhage is the main risk and cause of death in aplastic aneemia. Once the hsemoglobin level is raised to the reasonable point of 65% to 70%, transfusions should be given at regular intervals, say once a week or a fortnight as needed; this is better than waiting for the hmemoglobin to fall to 40% or so and accustoms the patient to a regime that may have to be carried on for some months. Red-cell aplasia is easier to control and has a better prognosis.
The patient with anemia due to methoin in our list was of this type and recovered after 6 transfusions of 1 pint of packed red cells; he has not relapsed for five years.
